⚖
Compare Funds
See how two funds stack up side by side, real returns, risk, cost and portfolio overlap.
VS
Key Metrics Comparison
| Metric | SBI Innovative Opportunities Fund - Growth - Direct Plan | HDFC Pharma and Healthcare Fund - Growth - Direct Plan |
|---|---|---|
| Snapshot | ||
| AMC | SBI MF | HDFC MF |
| Category | Equity - Thematic Fund - Other | Equity - Sectoral Fund - Pharma & Health Care |
| NAV | ₹10.63 (30 Oct 2026) | ₹21.95 (30 Oct 2026) |
| Rating | ★★★ | ★★★★★ |
| Benchmark | NIFTY 500 - TRI | BSE Health Care - TRI |
| Fund Manager | Vivek Gedda | Nikhil Mathur |
| Inception | 20 Aug 2024 | 04 Oct 2023 |
| Returns | ||
| 1Y | 5.05% | 22.64% |
| 3Y | — | 30.41% |
| 5Y | — | — |
| Since Inception | 2.96% | 29.15% |
| Risk | ||
| 17.12 | 14.07 | |
| 1.00 | 0.59 | |
| -0.06 | 1.59 | |
| 5.82 | 21.67 | |
| -0.10 | 3.48 | |
| -10.72% | -9.23% | |
| Costs | ||
| Expense Ratio | 1.05% | 1.03% |
| Exit Load | 1% on or before 30D, Nil after 30D | 1% on or before 30D, Nil after 30D |
| Min SIP | ₹500 | ₹100 |
| Min Lumpsum | ₹5,000 | ₹100 |
| Lock-in | None | None |
Min SIP is reported per fund, not per plan, every plan of a fund shares the same figure.
Portfolio Overlap
SBI MF91%
HDFC MF91%
9.0%Only 9.0% of holdings by weight are common between SBI MF and HDFC MF, based on each fund's top 20 disclosed holdings, not the full portfolio.
Common holdingSBI MFHDFC MF
Divi's Laboratories Ltd.5.44%9.39%
Sun Pharmaceutical Industries Ltd.3.54%8.28%
Category context: Equity vs Equity. Open the full Screener →